
feb pm et
summari rank one world largest pharmaceut compani offer wide rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
see
rais target
peer ep
estim set
ep vs ahead
estim sale exclud divestitur
hospira infus system rose
innov sale rose strong
eliqui xeljanz sale essenti health
sale fell gener price pressur
guid sale ep
use tax rate
reiter
decis regard consum healthcar
made loo cfa
risk assess reflect promin posit
global pharmaceut market afford
import competit oper financi
advantag howev compani still subject
inher risk common pharmaceut compani
relat discoveri develop
regulatori clearanc success commerci
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview growth sinc larg augment major acquisit --
warner-lambert pharmacia -- well in-licens product busi
significantli expand acquisit wyeth octob recent acquisit
includ hospira septemb billion mediv septemb billion
drug portfolio unmatch term breadth depth global drug market view
compani largest sell drug lyrica treatment nerv pain epilept seizur
prevnar/prevnar vaccin key drug includ ibranc treat breast cancer enbrel
treatment moder sever plaqu psoriasi rheumatoid arthriti sold outsid
 canada lipitor cholesterol-low agent largest-sel drug mani year
sale fell sharpli follow expir market exclus novemb
key drug sold includ viagra male erectil dysfunct norvasc antihypertens agent
sutent kidney cancer premarin femal hormon replac treatment benefix
recombin coagul therapi certain type hemophilia larg number drug
gener sale hundr million encompass treatment wide rang diseas
medic condit consum health care product includ over-the-counter medicin dietari supplement
item zoeti anim health unit spun sharehold
primari busi dynam adjust spend total billion billion
sale sale spend downtrend recent year
part on-going cost reduct program rose octob
pipelin consist compound total late-stag phase
registr compound includ new treatment wide rang condit includ cancer aid
obes arthriti heart diseas diabet schizophrenia pain
market profil dollar valu global drug market project grow compound-annual-growth-rate compound
annual growth rate period accord forecast made im
key driver emerg market whose aggreg sale countri project
advanc compound-annual-growth-rate period growth develop market spur
rise standard live grow govern spend health care howev im forecast
declin trend europ impact auster price combin drug spend five major
european market project declin compound-annual-growth-rate convers spend
 forecast grow compound-annual-growth-rate period
impact major develop mid-octob acquir rival drugmak wyeth
billion cash stock financ transact billion cash billion
debt billion common stock think acquisit significantli expand
exposur biolog vaccin new pharmaceut market view realiz estim
billion annual synergi wyeth integr februari acquir king
billion cash king brought pfizer grow portfolio novel pain treatment well
larg anim health product busi june acquir
billion septemb acquir mediv mdvn billion
financi trend early-februari made ipo offer million class share
interest zoeti new firm compris anim health divis late june
subsequ exchang remain million share interest million
share retir forma sale fallen billion billion
repres compound annual growth rate howev aid acquisit sale rose
billion oper ep declin repres
compound annual growth rate aid significantli cost cut stock repurchas
oper ep rose
cfo execut vice-president
chairman chief
gener counsel
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri howev
number new molecular entiti approv
declin robust approv
sinc record
approv follow robust approv
approv
 pharmaceut index
declin versu rise
composit index year-to-d
juli pharmaceut index
declin vs rise
fundament outlook pharmaceut
sub-industri next month posit
top-lin pressur patent expir
mani top-sel drug bottom
anticip modest sale increas
follow growth see
modest advers impact foreign exchang
follow firm
 dollar late also see
expand sale new innov drug
therapi margin improv accru
cost restructur merger synergi ep
comparison also benefit common
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev presid trump republican
made effort repeal replac
arr uncertain compon
surviv particularli individu
mandat medicaid expans may
hous repres pass
ahca would result million
peopl uninsur compar
june senat unveil healthcar
plan better reconcili act
bcra howev senat yet vote
bill cbo estim million
peopl would uninsur compar
hous senat plan would
elimin individu mandat phase
medicaid expans
despit advers effect patent expir
regulatori pressur high drug price
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
rais target peer
ep estim set ep vs
ahead estim sale exclud divestitur
hospira infus system rose innov health sale rose strong
eliqui xeljanz sale essenti health sale fell gener
price pressur guid sale ep
use tax rate reiter decis
regard consum healthcar made /jeffrey loo cfa
keep target forward
ep brand peer gener peer ep vs
line view sale account sale hospira infus
system fell innov health rose essenti health fell
say receiv approv next year
potenti blockbust half blockbust approv
think project overli optimist see aggress
keep target ep
estim brand peer gener peer ep
vs estim sale fell note less
sell day innov health sale rose solid ibranc sale
xtandi xeljanz sale expect howev see
increas competit ibranc recent approv drug essenti
health sale fell biosimilar sale driven inflectra rose
see similar trend brand gener sale throughout /jeffrey loo
februari board director pfizer inc elect ronald
blaylock serv member compani board director effect
immedi addit elect corpor govern committe
scienc technolog committe board mr blaylock
founder manag capit also held
senior manag posit ub painewebb group citicorp mr
blaylock also serv director carmax inc radio one inc
berkley inc well director syncreon
pfizer inc announc albert bourla name chief oper offic
effect januari albert bourla group presid
pfizer innov health busi sinc begin prior
current posit dr bourla group presid
vaccin oncolog consum healthcar busi
build strong competit posit oncolog expand
compani leadership vaccin cours career dr
bourla held number senior global posit across rang
busi geographi prior lead establish product busi
dr bourla area presid pfizer anim health busi
across europ africa asia pacif effect januari john
pfizer innov health angela hwang global presid gener manag
pfizer inflamm immunolog succeed john young group
presid pfizer essenti health mr young held number senior
leadership posit across includ presid primari
busi mr young report dr bourla continu member
compani execut leadership ms hwang join compani
compani corpor strateg plan polici group
experi includ leadership role within innov health
essenti health busi global presid pfizer inflamm
immunolog region head vaccin vice presid emerg
market primari busi vice presid brand
busi within essenti health current role respons
growth product xeljanz eucrisa build strong
pipelin around rheumatolog gastroenterolog dermatolog ms hwang
becom member compani execut leadership team report
dr bourla addit member execut leadership team
report dr bourla kirsten lund-jurgensen execut vice
presid presid pfizer global suppli rod mackenzi execut
presid strategi commerci oper
et cfra keep hold opinion share inc
keep target forward ep
estim ep vs ahead estim
rais ep estim
sale account divestitur hospira infus rose innov
sale rose essenti fell look essenti
sale improv anticip grow biosimilar sale strong
emerg market sale indic strateg decis regard
consum healthcar busi made /jeffrey loo cfa
said review strateg altern
consumer-health unit sell brand advil centrum
chapstick gener sale believ signific
interest numer buyer capabl pay believ
unit could fetch think would use proce pursu deal
brand pharma unit struggl slow growth lack
blockbust howev ceo ian read indic would prudent wait
see tax reform enact would impact valuat asset
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
